Global Health & Human Rights

Global Health Impact and Access to Essential Medicines

By Nicole Hassoun Ebola is ravaging parts of Africa, yet it is not the worst health problem facing people in the region. Millions more are infected with and die every year from diseases like malaria, TB, and HIV/AIDS because they cannot access the essential medicines they need. To change this, we need to understand where…

Published:

By Nicole Hassoun

Ebola is ravaging parts of Africa, yet it is not the worst health problem facing people in the region. Millions more are infected with and die every year from diseases like malaria, TB, and HIV/AIDS because they cannot access the essential medicines they need. To change this, we need to understand where we are succeeding in combating these diseases, and where we need to focus our efforts. Until now, this information has been sorely lacking.

Fortunately, the beta for a new Global Health Impact index has just launched that can help us address the access to medicines problem (check out: global-health-impact.org). Using the index, you can see the impact of the drugs for HIV, malaria, and TB in each country in the world. You can also get a sense for the overall impact we are having on the different diseases in the model. Finally, one can see drugs’ impacts by originator company.

Blog Photo

To create the rating system, researchers estimate the potential impact of each drug and aggregate drugs’ estimated impacts on global health as described above — by country, disease, and company. To do this, we use information on the need for different essential medicines (e.g., the death and disability due to the diseases they treat), information about access to the drugs (e.g., treatment percentages), and information about drug effectiveness (e.g., efficacy estimates).

You can learn more about the index on our website global-health-impact.org and check out our resources.

The Global Health Impact rating system opens the door to many new ways of increasing access to essential medicines. International organizations might use it in incentivizing stronger performance from country-level health systems in alleviating the burden of disease. Governmental and non-governmental organizations might use it to decide where it is best to focus their investments.

Researchers can partner with the Global Health Impact organization — a collaboration of scholars from universities and civil society organizations from around the world – to get a better picture of the causes and consequences of access to essential medicines.

Together we can improve our global health impact!

For some recent news about the project see:

https://www.marketplace.org/topics/health-care/new-effort-ranks-drug-makers-impact

https://blogs.wsj.com/pharmalot/2015/01/23/a-new-index-measures-impact-pharma-has-on-infectious-diseases/

https://www.capitalnewyork.com/article/albany/2015/01/8560712/suny-professor-indexes-pharma-companies-impact?news-image

 

About the author

  • Nicole Hassoun

    Nicole Hassoun is Professor of International Studies at Indiana University. She has held visiting positions at Cornell and Stanford Universities, the United Nations’ World Institute for Development Economics Research in Helsinki, the Center for Poverty Research in Salzburg, The Franco-Swedish Program in Philosophy and Economics in Paris and the Center for Advanced Studies in Frankfurt. She has published about a hundred papers in journals like the American Philosophical Quarterly, Journal of Development Economics, Tropical Medicine and International Health, Australasian Journal of Philosophy, The European Journal of Philosophy, and Philosophy and Economics. Her first book Globalization and Global Justice: Shrinking Distance, Expanding Obligations was published with Cambridge University Press in 2012 and her second book Global Health Impact: Extending Access on Essential Medicines for the Poor appeared with Oxford University Press in 2020.